News and Trends 3 Mar 2023 Porton and DanausGT look to boost development of gene and cell therapy Porton Advanced Solutions Ltd. and DanausGT Biotechnology Co., Ltd. have announced a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics. As an end-to-end gene and cell therapy service provider, Porton Advanced CDMO offers solutions covering plasmids, cell therapy, gene therapy, oncolytic viruses, mRNA therapy, and bacterial therapy. DanausGT […] March 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Mar 2023 Partnership formed to develop miRNA to treat pancreatic cancer RNA delivery and therapeutics company SiSaf Ltd is to collaborate with the University of Leipzig in Germany to develop targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer. The collaboration will combine SiSaf’s work in RNA delivery using its Bio-Courier silicon-stabilized hybrid lipid nanoparticles (sshLNPs) and the […] March 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2023 Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer. The clinical trial to be conducted by Peter Mac will be the first time a CAR-T cell therapy product […] February 28, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2023 Moderna and Life Edit Therapeutics look to speed up gene editing therapies Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio company focused on gene editing technologies and therapeutics, have announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary […] February 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Scancell looking to partner after positive COVID vaccine data Scancell Holdings plc, which develops novel immunotherapies for the treatment of cancer and infectious disease, has announced preliminary immunogenicity data from its phase 1 COVIDITY clinical trial at the University of Cape Town (UCT) Lung Institute in South Africa. The objectives of the trial were to assess the safety and immunogenicity of two vaccine candidates, […] February 14, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Syena created to deliver first-in-class TCR-NK cell therapy Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson Cancer Center, have launched Syena, a new oncology-focused product company pioneering T-cell receptor (TCR) natural killer (NK) cell therapies (TCR-NKs). Building on the intellectual property and technology from MD Anderson and Replay, Syena has the […] February 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Astex and Cardiff University Medicines Discovery Institute to collaborate on neurodegenerative diseases Astex Pharmaceuticals (UK), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system and The Medicines Discovery Institute, Cardiff University (MDI) have entered into a multi-year, multi-million-pound drug discovery research collaboration, aimed to identify new drugs to treat neurodegenerative diseases. The collaboration […] February 14, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023 Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study Heartseed Inc. and Novo Nordisk A/S say Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated four-week data on the patient, who lives with advanced heart failure and has given approval for […] February 10, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2023 Mnemo Therapeutics and Institut Curie studies lead to cancer-specific targets Mnemo Therapeutics, a French biotechnology company developing immunotherapies, has announced publication of two scientific studies developed at Institut Curie, its closest academic collaborator, in the journal Science Immunology. The publications reveal TE-exon splicing junctions act as a source of novel recurrent, cancer-specific targets and have potential implications for developing more effective and less toxic immunotherapies. […] February 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023 Orbit Discovery and Endevica Bio to develop cachexia therapeutics Orbit Discovery Limited has entered into a multi target research agreement with Endevica Bio Inc. Endevica creates first-in-class therapeutics for cachexia caused by cancer and other chronic conditions. Its lead compound has proven to be safe and well-tolerated in phase 1 trials. The collaboration aims to accelerate Endevica’s development of advanced G-protein coupled receptor (GPCR)-targeting […] February 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023 AstraZeneca creates FRAGLER for DNA synthesis “Plasmids are critical for so many processes in early drug discovery,” says David Öling, associate principal scientist at AstraZeneca. “From protein production, cell line engineering, CAR-T cell therapy, viral vector generation, therapeutic genome editing, mRNA/vaccine production and more. The time it takes and the cost of producing plasmids for DNA constructs is a critical limiting […] February 2, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 1 Feb 2023 Foundation for the National Institutes of Health: partnering to tackle cancer The Foundation for the National Institutes of Health (FNIH) takes on cancer through public-private research partnerships on prevention and early diagnosis. Dr Stacey Adam is associate vice president for research partnerships at the Foundation for the National Institutes of Health. In her role, she leads the cancer research partnership programs. Adam is a molecular pharmacologist/cancer […] February 1, 2023 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email